Published in Eur Radiol on December 22, 2009
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2013) 2.27
Radiomics: Images Are More than Pictures, They Are Data. Radiology (2015) 1.68
Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol (2012) 1.24
Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. Eur Radiol (2010) 1.21
Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol (2013) 0.94
Informatics in radiology: improving clinical work flow through an AIM database: a sample web-based lesion tracking application. Radiographics (2012) 0.93
MRI of Focal Liver Lesions. Curr Med Imaging Rev (2012) 0.93
Response evaluation after neoadjuvant chemoradiation by positron emission tomography-computed tomography for esophageal squamous cell carcinoma. Cancer Res Treat (2013) 0.85
Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review. Oncotarget (2016) 0.84
Comparison of manual and semi-automatic measuring techniques in MSCT scans of patients with lymphoma: a multicentre study. Eur Radiol (2014) 0.83
Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution. Oncol Lett (2013) 0.82
Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis. J Cancer (2015) 0.82
Dual-phase dual-energy CT in patients with lung cancer: assessment of the additional value of iodine quantification in lymph node therapy response. Eur Radiol (2014) 0.82
Comparison of the diagnostic performance of response evaluation criteria in solid tumor 1.0 with response evaluation criteria in solid tumor 1.1 on MRI in advanced breast cancer response evaluation to neoadjuvant chemotherapy. Korean J Radiol (2012) 0.82
Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study. Radiother Oncol (2012) 0.81
Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy. J Cancer (2015) 0.78
Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma. Neuro Oncol (2015) 0.78
Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child. Curr Oncol (2014) 0.78
Prognosis Relevance of Serum Cytokines in Pancreatic Cancer. Biomed Res Int (2015) 0.77
Experimental study of nasopharyngeal carcinoma radionuclide imaging and therapy using transferred human sodium/iodide symporter gene. PLoS One (2015) 0.77
The use of isolated limb infusion in limb threatening extremity sarcomas. Int J Hyperthermia (2012) 0.77
Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy. Eur Radiol (2016) 0.77
Pelvic lymphangioleiomyomatosis treated successfully with everolimus: Two case reports with literature review. Medicine (Baltimore) (2017) 0.75
Response Evaluation of Chemotherapy for Lung Cancer. Tuberc Respir Dis (Seoul) (2017) 0.75
Transarterial chemoembolization is ineffective for neuroendocrine tumors metastatic to the caudate lobe: a single institution review. World J Surg Oncol (2015) 0.75
Imaging and therapeutic applications of zinc(ii)-dipicolylamine molecular probes for anionic biomembranes. Chem Commun (Camb) (2016) 0.75
Effect of display magnification on perceived growth of liver lesions on computed tomography. J Digit Imaging (2012) 0.75
Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine. Hepat Med (2010) 0.75
Squamous cell carcinoma antigen expression in tumor cells is associated with the chemosensitivity and survival of patients with cervical cancer receiving docetaxel-carboplatin-based neoadjuvant chemotherapy. Oncol Lett (2017) 0.75
Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma. Clin Nucl Med (2017) 0.75
Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment. Radiat Oncol J (2017) 0.75
Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results. Radiol Med (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Reporting results of cancer treatment. Cancer (1981) 28.83
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med (2009) 12.92
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst (1999) 6.51
We should desist using RECIST, at least in GIST. J Clin Oncol (2007) 4.51
Standards for PET image acquisition and quantitative data analysis. J Nucl Med (2009) 4.37
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol (2003) 4.07
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol (2004) 3.72
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer (2007) 2.98
Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging (2006) 2.69
Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility. Eur Radiol (2003) 2.59
A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid (2008) 2.41
Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology (1992) 2.27
Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology (1991) 2.25
Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer (2008) 2.03
Assessing tumor response to therapy. J Nucl Med (2009) 1.95
Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer (2008) 1.94
Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR Am J Roentgenol (1996) 1.92
Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin Cancer Res (2003) 1.81
Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol (1985) 1.75
Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer (2008) 1.73
Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am (2009) 1.67
Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer (2004) 1.62
Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology (2005) 1.55
Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. Eur Radiol (2005) 1.55
Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med (2009) 1.54
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol (2002) 1.47
PET/CT for therapy response assessment in lymphoma. J Nucl Med (2009) 1.36
Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. Clin Radiol (2003) 1.29
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer (2004) 1.28
A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer (2008) 1.24
Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med (2009) 1.23
Pulmonary nodules: Interscan variability of semiautomated volume measurements with multisection CT-- influence of inspiration level, nodule size, and segmentation performance. Radiology (2007) 1.22
Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines. J Comput Assist Tomogr (2003) 1.09
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol (2008) 1.08
Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology? Br J Radiol (2003) 1.03
A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol (2004) 1.03
Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices. Comparison of semi-automated and manual measurement of RECIST and WHO criteria. Eur Radiol (2008) 1.01
The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol (2006) 1.00
Response to therapy in breast cancer. J Nucl Med (2009) 0.98
Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol (2002) 0.98
Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV--a feasibility study. Eur Radiol (2008) 0.98
Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate (2005) 0.95
Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. Ann Oncol (2006) 0.93
Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results. Eur Radiol (2003) 0.92
Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients. Cancer Sci (2006) 0.90
Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer. Br J Cancer (2002) 0.88
Sequential changes after radiofrequency ablation and cryoablation of renal neoplasms: role of CT and MR imaging. Radiographics (2007) 0.86
Imaging after radiofrequency ablation of hepatic tumors. Semin Ultrasound CT MR (2009) 0.82
Reliability of tumor volume estimation from MR images in patients with malignant glioma. Results from the American College of Radiology Imaging Network (ACRIN) 6662 Trial. Eur Radiol (2008) 0.81
Morphological characteristics of lateral pelvic lymph nodes in rectal carcinoma. Langenbecks Arch Surg (2007) 0.81
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Osteoarthritis of the knee: association between clinical features and MR imaging findings. Radiology (2006) 2.62
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol (2010) 2.61
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer (2011) 2.23
Technical considerations in CT-guided radiofrequency thermal ablation of osteoid osteoma: tricks of the trade. AJR Am J Roentgenol (2002) 2.10
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol (2009) 1.78
MRI assessment of knee osteoarthritis: Knee Osteoarthritis Scoring System (KOSS)--inter-observer and intra-observer reproducibility of a compartment-based scoring system. Skeletal Radiol (2004) 1.76
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab (2010) 1.72
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res (2008) 1.60
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol (2009) 1.60
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res (2010) 1.57
Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev (2009) 1.57
Bone marrow edema-like lesions change in volume in the majority of patients with osteoarthritis; associations with clinical features. Eur Radiol (2007) 1.53
Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer (2014) 1.51
Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer (2004) 1.49
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48
The clinical approach toward giant cell tumor of bone. Oncologist (2014) 1.46
Metastases of colorectal carcinoma: comparison of soft- and hard-copy helical CT interpretation. Radiology (2003) 1.45
Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases. J Thorac Oncol (2014) 1.42
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer (2011) 1.41
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res (2004) 1.36
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33
Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging (2002) 1.33
Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology (2004) 1.31
Osteoid osteoma: clinical results with thermocoagulation. Radiology (2002) 1.31
Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer (2010) 1.27
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol (2009) 1.26
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res (2011) 1.24
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs (2014) 1.24
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23
Osteoid osteoma: factors for increased risk of unsuccessful thermal coagulation. Radiology (2004) 1.22
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist (2011) 1.22
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
Effectiveness of MR imaging in selection of patients for arthroscopy of the knee. Radiology (2002) 1.19
Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer (2010) 1.17
Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther (2005) 1.15
Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res (2009) 1.14
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther (2004) 1.13
Epidemiology of Norwalk-like virus infections in cattle in The Netherlands. Vet Microbiol (2003) 1.13
Value of dynamic contrast-enhanced MR imaging in diagnosing and classifying peripheral vascular malformations. AJR Am J Roentgenol (2002) 1.11
Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist (2011) 1.11
Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res (2011) 1.07
Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol (2006) 1.07
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer (2011) 1.06
Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer (2010) 1.06
Positive association between increased popliteal artery vessel wall thickness and generalized osteoarthritis: is OA also part of the metabolic syndrome? Skeletal Radiol (2009) 1.05
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol (2008) 1.05
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol (2014) 1.02
Tales of how great drugs were brought down by a flawed rationale--letter. Clin Cancer Res (2013) 1.02
Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature. J Cutan Pathol (2008) 1.02
US examination of the appendix in children with suspected appendicitis: the additional value of secondary signs. Eur Radiol (2008) 1.02
Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev (2008) 1.01
Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today (2011) 1.01
Quantitative analysis of focal masses at MR imaging: a plea for standardization. Radiology (2004) 0.99
Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother (2011) 0.99
Comparison of quantitative cartilage measurements acquired on two 3.0T MRI systems from different manufacturers. J Magn Reson Imaging (2006) 0.99
Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol (2013) 0.98
Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today (2007) 0.97
Clinical consequences of bone bruise around the knee. Eur Radiol (2005) 0.97
MRI of adamantinoma of long bones in correlation with histopathology. AJR Am J Roentgenol (2004) 0.96
Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. Sarcoma (2012) 0.95
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol (2012) 0.95
Radiofrequency ablation of spinal osteoid osteoma: clinical outcome. Spine (Phila Pa 1976) (2009) 0.95
Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.93
Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results. Eur Radiol (2003) 0.92
Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res (2005) 0.92
Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. Support Care Cancer (2013) 0.92
Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. Hematol Oncol Clin North Am (2013) 0.91
Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol (2011) 0.90
A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.90
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer (2015) 0.90
Aiming for a simpler early arthritis MRI protocol: can Gd contrast administration be eliminated? Eur Radiol (2015) 0.89
Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res (2013) 0.89
Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol (2010) 0.89
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res (2007) 0.89
Vascular tumors of bone: imaging findings. Eur J Radiol (2010) 0.89
Osteosarcoma: evolution of treatment paradigms. Sarcoma (2013) 0.88
Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability. Clin Orthop Relat Res (2002) 0.88
Magnetic resonance imaging of knee cartilage using a water selective balanced steady-state free precession sequence. J Magn Reson Imaging (2004) 0.88
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer (2012) 0.88
A novel system for efficient gene transfer into primary human hepatocytes via cell-permeable hepatitis B virus-like particle. Hepatology (2005) 0.88
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res (2005) 0.88
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemother Pharmacol (2014) 0.87
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer (2008) 0.87
MRI of hand and foot joints of patients with anticitrullinated peptide antibody positive arthralgia without clinical arthritis. Ann Rheum Dis (2013) 0.87
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol (2008) 0.87
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. Int J Cancer (2014) 0.87
Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. Pharmacogenomics (2013) 0.86
Aiming for a shorter rheumatoid arthritis MRI protocol: can contrast-enhanced MRI replace T2 for the detection of bone marrow oedema? Eur Radiol (2014) 0.86
Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm (2011) 0.85
A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal. J Surg Oncol (2012) 0.85
Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discov Today (2010) 0.85
Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup. Virchows Arch (2012) 0.84
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial. Breast Cancer Res Treat (2014) 0.84